Literature DB >> 8378346

Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.

Z Dominski1, R Kole.   

Abstract

Antisense 2'-O-methylribooligonucleotides were targeted against specific sequence elements in mutated human beta-globin pre-mRNAs to restore correct splicing of these RNAs in vitro. The following mutations of the beta-globin gene, A-->G at nt 110 of the first intron (beta 110), T-->G at nt 705 and C-->T at nt 654 of the second intron (IVS2(705) and IVS2(654), respectively), which led to aberrant splicing of the corresponding pre-mRNAs, were previously identified as the underlying causes of beta-thalassemia. Aberrant splicing of beta 110 pre-mRNA was efficiently reversed by an oligonucleotide targeted against the branch point sequence in the first intron of the pre-mRNA but not by an oligonucleotide targeted against the aberrant 3' splice site. In both IVS2(705) and IVS2(654) pre-mRNAs, correct splicing was restored by oligonucleotides targeted against the aberrant 5' splice sites created by the mutations in the second intron or against a cryptic 3' splice site located upstream and activated in the mutated background. These experiments represent an approach in which antisense oligonucleotides are used to restore the function of a defective gene and not, as usual, to down-regulate the expression of an undesirable gene.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8378346      PMCID: PMC47420          DOI: 10.1073/pnas.90.18.8673

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

Review 1.  Oligodeoxynucleotides as antisense inhibitors of gene expression.

Authors:  M K Ghosh; J S Cohen
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1992

Review 2.  Antisense inhibitors of HIV: problems and perspectives.

Authors:  G Degols; J P Leonetti; P Milhaud; N Mechti; B Lebleu
Journal:  Antiviral Res       Date:  1992-04       Impact factor: 5.970

Review 3.  Antisense antivirals.

Authors:  J Goodchild
Journal:  Antisense Res Dev       Date:  1991

Review 4.  Oligonucleotide-directed DNA triple-helix formation: an approach to artificial repressors?

Authors:  L J Maher; B Wold; P B Dervan
Journal:  Antisense Res Dev       Date:  1991

5.  Abnormally spliced messenger RNA in erythroid cells from patients with beta+ thalassemia and monkey cells expressing a cloned beta+-thalassemic gene.

Authors:  Y Fukumaki; P K Ghosh; E J Benz; V B Reddy; P Lebowitz; B G Forget; S M Weissman
Journal:  Cell       Date:  1982-03       Impact factor: 41.582

6.  Recognition of cap structure in splicing in vitro of mRNA precursors.

Authors:  M M Konarska; R A Padgett; P A Sharp
Journal:  Cell       Date:  1984-10       Impact factor: 41.582

7.  Normal and mutant human beta-globin pre-mRNAs are faithfully and efficiently spliced in vitro.

Authors:  A R Krainer; T Maniatis; B Ruskin; M R Green
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

8.  Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.

Authors:  C F Bennett; M Y Chiang; H Chan; J E Shoemaker; C K Mirabelli
Journal:  Mol Pharmacol       Date:  1992-06       Impact factor: 4.436

9.  beta-Thalassemia in Chinese: use of in vivo RNA analysis and oligonucleotide hybridization in systematic characterization of molecular defects.

Authors:  T C Cheng; S H Orkin; S E Antonarakis; M J Potter; J P Sexton; A F Markham; P J Giardina; A Li; H H Kazazian
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

10.  Intron sequences involved in lariat formation during pre-mRNA splicing.

Authors:  R Reed; T Maniatis
Journal:  Cell       Date:  1985-05       Impact factor: 41.582

View more
  136 in total

1.  Sensitivity of splice sites to antisense oligonucleotides in vivo.

Authors:  H Sierakowska; M J Sambade; D Schümperli; R Kole
Journal:  RNA       Date:  1999-03       Impact factor: 4.942

2.  Insertion of disease-causing mutations in BACs by homologous recombination in Escherichia coli.

Authors:  M Nefedov; R Williamson; P A Ioannou
Journal:  Nucleic Acids Res       Date:  2000-09-01       Impact factor: 16.971

3.  Temperature-dependent splicing of beta-globin pre-mRNA.

Authors:  Federica Gemignani; Peter Sazani; Paul Morcos; Ryszard Kole
Journal:  Nucleic Acids Res       Date:  2002-11-01       Impact factor: 16.971

4.  Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment.

Authors:  Jagjeet K Kang; Alberto Malerba; Linda Popplewell; Keith Foster; George Dickson
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

Review 5.  Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing.

Authors:  Mariano A Garcia-Blanco
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

6.  Muscular dystrophy: A hidden ancestral legacy trumped.

Authors:  Masayuki Nakamori; Charles Thornton
Journal:  Nature       Date:  2011-10-05       Impact factor: 49.962

7.  Antisense oligonucleotide-based therapy in human erythropoietic protoporphyria.

Authors:  Vincent Oustric; Hana Manceau; Sarah Ducamp; Rima Soaid; Zoubida Karim; Caroline Schmitt; Arienne Mirmiran; Katell Peoc'h; Bernard Grandchamp; Carole Beaumont; Said Lyoumi; François Moreau-Gaudry; Véronique Guyonnet-Dupérat; Hubert de Verneuil; Joëlle Marie; Herve Puy; Jean-Charles Deybach; Laurent Gouya
Journal:  Am J Hum Genet       Date:  2014-03-27       Impact factor: 11.025

Review 8.  Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials.

Authors:  Yuko Shimizu-Motohashi; Shouta Miyatake; Hirofumi Komaki; Shin'ichi Takeda; Yoshitsugu Aoki
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

9.  Future alternative therapies for β-thalassemia.

Authors:  Stefano Rivella; Eliezer Rachmilewitz
Journal:  Expert Rev Hematol       Date:  2009-12-01       Impact factor: 2.929

10.  Rational design of antisense oligomers to induce dystrophin exon skipping.

Authors:  Chalermchai Mitrpant; Abbie M Adams; Penny L Meloni; Francesco Muntoni; Sue Fletcher; Steve D Wilton
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.